Moderna Inc. [NASDAQ: MRNA] stock went on a downward path that fall over -5.23% on Monday, amounting to a one-week price decrease of less than -5.54%. The company report on June 15, 2021 that Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship’s Preemptive Medicine and Health Security Initiative.
Flagship Pioneering, the bioplatform innovation company, announced that Stephen Hahn, M.D. will help lead its Preemptive Medicine and Health Security initiative as Chief Medical Officer, and join Flagship’s Senior Leadership Team, effective June 16, 2021. Dr. Hahn served as the U.S. Food and Drug Administration Commissioner from 2019–2021. Prior to joining the FDA, he was the Chief Medical Executive, The University of Texas MD Anderson Cancer Center.
During his time as the 24th Commissioner of the U.S. Food and Drug Administration, Dr. Hahn led the 17,000+ person agency that regulates approximately 20 percent of consumer spending in the United States. He oversaw both COVID and non-COVID regulatory affairs, including therapeutics and vaccine development, devices, diagnostics, and clinical trials.
Over the last 12 months, MRNA stock rose by 234.53%. The one-year Moderna Inc. stock forecast points to a potential downside of -16.31. The average equity rating for MRNA stock is currently 2.60, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $82.58 billion, with 400.00 million shares outstanding and 362.61 million shares in the current float. Compared to the average trading volume of 9.47M shares, MRNA stock reached a trading volume of 11714861 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Moderna Inc. [MRNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $178.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on February 01, 2021. The new note on the price target was released on December 16, 2020, representing the official price target for Moderna Inc. stock. Previously, the target price had yet another raise from $90 to $150, while Jefferies kept a Hold rating on MRNA stock.
The Average True Range (ATR) for Moderna Inc. is set at 11.79, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 30.23. The Price to Book ratio for the last quarter was 21.61, with the Price to Cash per share for the same quarter was set at 19.43. Price to Free Cash Flow for MRNA in the course of the last twelve months was 16.49 with Quick ratio for the last quarter at 1.30.
MRNA Stock Performance Analysis:
Moderna Inc. [MRNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.54. With this latest performance, MRNA shares gained by 38.39% in over the last four-week period, additionally plugging by 33.22% over the last 6 months – not to mention a rise of 234.53% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 63.50, with the RSI for the last a single of trading hit 61.53, and the three-weeks RSI is set at 62.83 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 171.02, while it was recorded at 214.74 for the last single week of trading, and 127.85 for the last 200 days.
Insight into Moderna Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc. [MRNA] shares currently have an operating margin of -94.99 and a Gross Margin at +95.12. Moderna Inc.’s Net Margin is presently recorded at -92.99.
Return on Total Capital for MRNA is now -37.14, given the latest momentum, and Return on Invested Capital for the company is -36.66. Return on Equity for this stock declined to -39.99, with Return on Assets sitting at -16.74. When it comes to the capital structure of this company, Moderna Inc. [MRNA] has a Total Debt to Total Equity ratio set at 9.28. Additionally, MRNA Total Debt to Total Capital is recorded at 8.49, with Total Debt to Total Assets ending up at 3.24. Long-Term Debt to Equity for the company is recorded at 8.09, with the Long-Term Debt to Total Capital now at 7.41.
Reflecting on the efficiency of the workforce at the company, Moderna Inc. [MRNA] managed to generate an average of -$574,665 per employee. Receivables Turnover for the company is 1.13 with a Total Asset Turnover recorded at a value of 0.18.Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.40.
MRNA Stock EPS
With the latest financial reports released by the company, Moderna Inc. posted -0.31/share EPS, while the average EPS was predicted by analysts to be reported at -0.35/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 11.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moderna Inc. go to 16.80%.
Moderna Inc. [MRNA] Insider Position Details
There are presently around $43,553 million, or 53.70% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 45,337,764, which is approximately 86.481% of the company’s market cap and around 2.50% of the total institutional ownership; BLACKROCK INC., holding 20,803,397 shares of the stock with an approximate value of $4.31 billion in MRNA stocks shares; and FLAGSHIP PIONEERING INC., currently with $4.27 billion in MRNA stock with ownership of nearly -33.333% of the company’s market capitalization.
Positions in Moderna Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 464 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 42,477,262 shares. Additionally, 319 investors decreased positions by around 31,244,656 shares, while 87 investors held positions by with 136,261,642 shares. The mentioned changes placed institutional holdings at 209,983,560 shares, according to the latest SEC report filing. MRNA stock had 176 new institutional investments in for a total of 5,875,965 shares, while 98 institutional investors sold positions of 1,619,216 shares during the same period.